Advanced search    

Search: authors:"T. Lauritzen"

23 papers found.
Use AND, OR, NOT, +word, -word, "long phrase", (parentheses) to fine-tune your search.

HbA1c and cardiovascular risk score identify people who may benefit from preventive interventions: a 7 year follow-up of a high-risk screening programme for diabetes in primary care (ADDITION), Denmark

, and was until late 2010 director of the Steno Diabetes Centre, which is owned by Novo Nordisk and holds shares in Novo Nordisk. T. Lauritzen has been lecturing for Novo Nordisk, holds shares in Novo

The pro-inflammatory biomarker soluble urokinase plasminogen activator receptor (suPAR) is associated with incident type 2 diabetes among overweight but not obese individuals with impaired glucose regulation: effect modification by smoking and body weight status

Aims/hypothesisRecent evidence links the soluble urokinase plasminogen activator receptor (suPAR), a stable biomarker of systemic immune activation, to several chronic diseases, including type 2 diabetes. suPAR is also associated with adiposity and smoking. We hypothesised that this biomarker would be linked to incident type 2 diabetes in individuals with impaired glucose...

Determinants of progression from impaired fasting glucose and impaired glucose tolerance to diabetes in a high-risk screened population: 3 year follow-up in the ADDITION study, Denmark

holds shares in Novo Nordisk A/S. He has received lecture fees from Novo Nordisk, Bristol-Myers Squibb, Novartis, Pfizer, Hermedico and AstraZeneca. T. Lauritzen has received lecture fees of approximately

Progression from impaired fasting glucose and impaired glucose tolerance to diabetes in a high-risk screening programme in general practice: the ADDITION Study, Denmark

S. S. Rasmussen C. Glmer A. Sandbaek T. Lauritzen K. Borch-Johnsen Aims/hypothesis To estimate the 1-year progression rates from both IFG and IGT to diabetes in individuals identified in a pragmatic

Review of prandial glucose regulation with repaglinide: a solution to the problem of hypoglycaemia in the treatment of Type 2 diabetes?

Type 2 diabetes mellitus is characterised by abnormal beta-cell function (present at the time of diagnosis) that is often associated with insulin resistance. An important and consistent pathophysiological finding is the failure to produce adequate increments in insulin secretion in response to carbohydrate intake. Therefore, insulin secretagogue therapy, particularly when focused...

Population-based stepwise screening for unrecognised Type 2 diabetes is ineffective in general practice despite reliable algorithms

Aims/hypothesisThe yield of screening programmes for Type 2 diabetes in the existing healthcare setting might be lower than anticipated from tests of screening algorithms in data from epidemiological surveys. Our aims were to evaluate the reliability of the algorithms and the effectiveness of a proposed stepwise screening programme for Type 2 diabetes in general practice...

Combined analysis of 19 common validated type 2 diabetes susceptibility gene variants shows moderate discriminative value and no evidence of gene–gene interaction

Aims/hypothesis The list of validated type 2 diabetes susceptibility variants has recently been expanded from three to 19. The variants identified are common and have low penetrance in the general population. The aim of the study is to investigate the combined effect of the 19 variants by applying receiver operating characteristics (ROC) to demonstrate the discriminatory value...

Impact of polymorphisms in WFS1 on prediabetic phenotypes in a population-based sample of middle-aged people with normal and abnormal glucose regulation

Aim/hypothesisRecently, variants in WFS1 have been shown to be associated with type 2 diabetes. We aimed to examine metabolic risk phenotypes of WFS1 variants in glucose-tolerant people and in individuals with abnormal glucose regulation.MethodsThe type 2 diabetes-associated WFS1 variant rs734312 (His611Arg) was studied in the population-based Inter99 cohort involving 4,568...

The ADDITION study: proposed trial of the cost-effectiveness of an intensive multifactorial intervention on morbidity and mortality among people with Type 2 diabetes detected by screening

Obesity was sponsored by Novo Nordisk A=S 6 ADDITION: Anglo-Danish-Dutch Study of Intensive Treatment In People with Screen Detected Diabetes in Primary Care. Principal investigators: T Lauritzen and K

Patient and provider perceptions of care for diabetes: results of the cross-national DAWN Study

-of-care improvement activities (see http://www.dawnstudy. com). M. Peyrot performed the statistical analysis. M. Peyrot and R. R. Rubin drafted the paper. T. Lauritzen, S. E. Skovlund, F. J. Snoek, D ... M. Peyrot are on the International DAWN Advisory Panel. M. Peyrot, R. R. Rubin, T. Lauritzen and R. Landgraf have received grants, and fees for consulting and lecturing from Novo Nordisk, the sponsor

The GCKR rs780094 polymorphism is associated with elevated fasting serum triacylglycerol, reduced fasting and OGTT-related insulinaemia, and reduced risk of type 2 diabetes

Aims/hypothesisRecent genome-wide association studies have suggested that a polymorphism in GCKR, the gene encoding the glucokinase regulatory protein, is involved in triacylglycerol regulation. Our aim was to examine in large-scale studies the common GCKR rs780094 polymorphism in relation to metabolic traits (mainly fasting hypertriacylglycerolaemia) and traits related to...

A role for coding functional variants in HNF4A in type 2 diabetes susceptibility

for Diabetes, Endocrinology and Metabolism (OCDEM), University of Oxford, Churchill Hospital , Old Road, Headington, Oxford OX3 7LJ, UK 1 T. Lauritzen Department of General Practice, University of ... , Gentofte, Denmark (principal investigator), T. Lauritzen, University of Aarhus, Denmark (principal investigator) and A. Sandbk, University of Aarhus, Aarhus, Denmark. The study was supported by the National

Effect of improved metabolic control on loss of kidney function in Type 1 (insulin-dependent) diabetic patients: an update of the Steno studies

. Mathiesen T. Jensen T. Lauritzen T. Deckert Steno Memorial Hospital Gentofte Denmark Summary. We re-examined 69 of the 70 patients entering the two independent Steno Studies of effects of improved metabolic ... , Oxenbr R , Johansen K , Svendsen PA , Deckert T ( 1984 ) Incipient nephropathy in Type 1 (insulin-dependent) diabetes . Diabetologia 26 : 406 - 410 18. Deckert T , Lauritzen T , Parving H-H , Christiansen

Pharmacokinetics of continuous subcutaneous insulin infusion

Diabetologia Pharmacokinetics of Continuous Subcutaneous Insulin Infusion 0 Steno Memorial Hospital and Hagedorn Research Laboratory , Gentofte , Denmark 1 T. Lauritzen, S. P r a m m i n g , T. D e


. University Hospltal Leiden , The, Netherlands., TREATMENT WITH hGH IIAS NO EFFECT ON ADULT HEIGHT IN, IIYPOPITUITARY CIIILDREN 3 T. Lauritzen*, H. Orskov* (Introd. by N. Skakkebzk)., Second University Clinic


T. Lauritzen*, JOL. Jsrgensen*, A. Flyvbjerg*, JS. 0 J.J. VAN DER WERFF TEN BOSCH and A. DOT 1 JOL. Jorgensen*, JS. Christiansen*, A. Flyvbjerg*, 2 0 Christiansen*. H. Orskov* ( I n t r o d . by N ... Department of, Endocrinology. University Hospltal Leiden , The , Netherlands. , TREATMENT WITH hGH IIAS NO EFFECT ON ADULT HEIGHT I N, IIYPOPITUITARY CIIILDREN 2 T. Lauritzen*, H. Orskov* ( I n t r o d . by N

Variation in125i-insulin absorption and blood glucose concentration

d insulin a b s o r b e d in t h e p r e c e d i n g 3 to 6 h o u r s was f o u n d in all p a t i e n t s ( T a b l e 3), b e i n g 0.73 for t h e p a t i e n t in T. Lauritzen et 'al.: t25I-Insulin ... statistically T. Lauritzen et al.: ~25I-Insulin Absorption and Blood Glucose Concentration significant at the 5% level in all but one patient. The latter patient [ 1 ] had only been treated with insulin for 2

Glycosylated haemoglobin and steady-state mean blood glucose concentration in type 1 (insulin-dependent) diabetes

Diabetologia Glycosylated Haemoglobin a n d Steady-State Mean Blood Glucose Concentration in Type 1 (Insulin-Dependent) Diabetes P. A a b y Svendsen T. Lauritzen U. S o e g a a r d a n d J. N e r u


J.O.L. Jergensen*. J. Meller*. T. Lauritzen*. &J 0 A. Massarano*, R. Stanhope, P.J. Pringle*, 1 0 Christiansen* (Introd. by N.E. Skakkebek)., Second University Clinic of Internal Medicine.Aarhus